Please assess the completion status of the following clinical trial:

Trial Title: Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age at birth 23 0/7 to 27 6/7 weeks by best obstetrical dating~2. No previous exposure to indomethacin~3. Clinical determination to use indomethacin to attempt closure of PDA~4. No known congenital abnormalities involving the kidneys, heart or lungs~5. No preexisting renal dysfunction, defined as serum creatinine \> 1.0 mg/dl, or urine output \<1.0 ml/kg/hour over the previous 24 hours.~Exclusion Criteria:~1. Enrollment in concurrent study in which interventions may contribute confounding variables or have competing outcomes~2. Infants with antenatally or postnatally diagnosed renal or urinary tract abnormalities~3. Infants with umbilical cord or infant blood pH below 7.0 at any time before enrollment~4. Attending physician unwilling to have infant participate in study~5. Absence of informed consent

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
- Fenoldopam (Type: EXPERIMENTAL): Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).